BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCRX BioCryst制药

盘后交易 02-05 16:02:47 EST

6.24

-0.18

-2.80%

盘后6.24

+0.000.00%

16:02 EST

最高6.57	最低6.23	成交量450.92万
今开6.44	昨收6.42	日振幅5.30%
总市值15.48亿	流通市值13.60亿	总股本2.48亿
成交额2,852万	换手率2.07%	流通股本2.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"BioCryst制药","latestPrice":6.24,"timestamp":1770325200000,"preClose":6.42,"halted":0,"volume":4509195,"hourTrading":{"tag":"盘后","latestPrice":6.24,"preClose":6.24,"latestTime":"16:02 EST","volume":35873,"amount":223847.52000000002,"timestamp":1770325342631,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.028037383177570048,"floatShares":218000000,"shares":248000000,"eps":-0.045319,"marketStatus":"盘后交易","change":-0.18,"latestTime":"02-05 16:02:47 EST","open":6.44,"high":6.57,"low":6.23,"amount":28522108.9830315,"amplitude":0.05296,"askPrice":7.5,"askSize":500,"bidPrice":6.19,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-0.045319,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770339600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":6.42,"preHourTrading":{"tag":"盘前","latestPrice":6.6,"preClose":6.42,"latestTime":"09:19 EST","volume":26671,"amount":172553.1366623,"timestamp":1770301152640,"change":0.18,"changeRate":0.028037,"amplitude":0.031153},"postHourTrading":{"tag":"盘后","latestPrice":6.24,"preClose":6.24,"latestTime":"16:02 EST","volume":35873,"amount":223847.52000000002,"timestamp":1770325342631,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.173584,"impliedVol":0.5533,"impliedVolPercentile":0.6733},"requestUrl":"/m/hq/s/BCRX/wiki","defaultTab":"wiki","newsList":[{"id":"2604946453","title":"BioCryst制药盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604946453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604946453?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:38","pubTimestamp":1768574319,"startTime":"0","endTime":"0","summary":"北京时间2026年01月16日22时38分，BioCryst制药股票出现波动，股价大幅下挫5.09%。截至发稿，该股报6.81美元/股，成交量25.863万股，换手率0.12%，振幅4.95%。BioCryst制药股票所在的制药行业中，整体跌幅为0.09%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116223839a7236958&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116223839a7236958&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2603863758","title":"BioCryst制药盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603863758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603863758?lang=zh_cn&edition=full","pubTime":"2026-01-14 01:51","pubTimestamp":1768326667,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日01时51分，BioCryst制药股票出现波动，股价大幅下跌5.01%。截至发稿，该股报6.74美元/股，成交量342.772万股，换手率1.63%，振幅5.64%。BioCryst制药股票所在的制药行业中，整体跌幅为0.08%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114015107a716c1e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114015107a716c1e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"1191616863","title":"BioCryst制药公布2025年Orladeyo®（贝罗曲司他）初步全年净收入6.01亿美元，同比增长37%，超出此前指引区间","url":"https://stock-news.laohu8.com/highlight/detail?id=1191616863","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191616863?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:04","pubTimestamp":1768219443,"startTime":"0","endTime":"0","summary":"BioCryst制药宣布，其药物Orladeyo®（贝罗曲司他）在2025年初步实现净收入6.01亿美元，较上年同期增长37%，表现优于公司先前公布的业绩指引范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BK4588","BCRX","BK4213","BK4585","RRC"],"gpt_icon":0},{"id":"1161126619","title":"BioCryst公布Orladeyo®（Berotralstat）口服颗粒获得FDA批准，成为唯一的针对2至12岁Hae患者的口服预防治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1161126619","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161126619?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:01","pubTimestamp":1765540901,"startTime":"0","endTime":"0","summary":"BioCryst公布Orladeyo®（Berotralstat）口服颗粒获得FDA批准，成为唯一的针对2至12岁Hae患者的口服预防治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"1105115227","title":"BioCryst在Acaai上发布新数据，突显Hae对儿童患者和照顾者的负担以及使用Orladeyo®（Berotralstat）治疗一年后儿童攻击次数的持续减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1105115227","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105115227?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:02","pubTimestamp":1762434127,"startTime":"0","endTime":"0","summary":"BioCryst在Acaai上发布新数据，突显Hae对儿童患者和照顾者的负担以及使用Orladeyo®（Berotralstat）治疗一年后儿童攻击次数的持续减少","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"gpt_icon":0},{"id":"2581066048","title":"BioCryst制药盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581066048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581066048?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:47","pubTimestamp":1762354025,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日22时47分，BioCryst制药股票出现异动，股价大幅上涨5.03%。BioCryst制药股票所在的制药行业中，整体涨幅为1.33%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。消息层面，截至22时47分，《Citizens JMP维持BioCryst制药买入评级，下调目标价至25美元》资讯为影响BioCryst制药的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105224706a6e37e42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105224706a6e37e42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"1188729715","title":"异动解读 | BioCryst制药股价盘中大跌5.03%，分析师下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1188729715","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188729715?lang=zh_cn&edition=full","pubTime":"2025-11-04 23:34","pubTimestamp":1762270497,"startTime":"0","endTime":"0","summary":"BioCryst制药（股票代码：BCRX）周二盘中股价大跌5.03%，引发投资者关注。该跌幅主要受到多家券商分析师下调目标价的影响。\n\n据悉，投资银行Needham将BioCryst的目标价从20美元下调至18美元。同时，巴克莱银行也将该公司的目标价从11美元下调至9美元。这些目标价的下调反映了分析师对公司未来前景的谨慎态度。\n\nBioCryst制药主要专注于开发用于治疗罕见病的口服药物。目标价的下调可能反映了分析师对公司产品管线或市场前景的担忧。然而，具体原因尚未在公开信息中披露。投资者可能需要关注公司未来的财报和产品开发进展，以更好地评估其长期发展前景。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCRX"],"gpt_icon":0},{"id":"1126472474","title":"BioCryst制药第三季度每股收益为0.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126472474","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126472474?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:15","pubTimestamp":1762172140,"startTime":"0","endTime":"0","summary":"11月03日 - BioCryst制药第三季度产品销售额为1.594亿元美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"1139404838","title":"BioCryst制药：下调2025年调整后运营费用预期至4.3亿至4.4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139404838","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139404838?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:09","pubTimestamp":1762171747,"startTime":"0","endTime":"0","summary":"BioCryst制药：下调2025年调整后运营费用预期至4.3亿至4.4亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"1171912093","title":"BioCryst制药：将2025财年全球Orladeyo净收入预期上调至590百万至600百万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171912093","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171912093?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:09","pubTimestamp":1762171747,"startTime":"0","endTime":"0","summary":"BioCryst制药：将2025财年全球Orladeyo净收入预期上调至590百万至600百万美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"gpt_icon":0},{"id":"1116356134","title":"BioCryst制药：公司有望在2025年实现净收入和正现金流","url":"https://stock-news.laohu8.com/highlight/detail?id=1116356134","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116356134?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:09","pubTimestamp":1762171745,"startTime":"0","endTime":"0","summary":"BioCryst制药：公司有望在2025年实现净收入和正现金流","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"1159910814","title":"Astria Therapeutics Inc：预计交易对价现金部分将通过现有资金及Blackstone融资安排提供支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1159910814","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159910814?lang=zh_cn&edition=full","pubTime":"2025-10-14 19:02","pubTimestamp":1760439748,"startTime":"0","endTime":"0","summary":"Astria Therapeutics Inc：预计交易对价现金部分将通过现有资金及Blackstone融资安排提供支持","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","ATXS","BK4139","BCRX"],"gpt_icon":0},{"id":"1100362202","title":"BioCryst制药公司与BioCryst Ireland签署商标许可协议 - SEC申报文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1100362202","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100362202?lang=zh_cn&edition=full","pubTime":"2025-10-01 20:08","pubTimestamp":1759320511,"startTime":"0","endTime":"0","summary":"BioCryst制药公司与BioCryst Ireland签署商标许可协议 - SEC申报文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2558502444","title":"BioCryst制药2025财年第二财季实现净利润5.09百万美元，同比增加140.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558502444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558502444?lang=zh_cn&edition=full","pubTime":"2025-08-10 00:01","pubTimestamp":1754755290,"startTime":"0","endTime":"0","summary":"8月10日，BioCryst制药公布财报，公告显示公司2025财年第二财季净利润为5.09百万美元，同比增加140.17%；其中营业收入为1.63亿美元，同比增加49.54%，每股基本收益为0.02美元。从资产负债表来看，BioCryst制药总负债8.79亿美元，其中短期债务37.75百万美元，资产负债比为0.52，流动比率为2.25。机构评级：截至2025年8月10日，当前有11家机构对BioCryst制药目标价做出预测，其中目标均价为16.73美元，其中最低目标价为11.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000331a47efc48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000331a47efc48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX"],"gpt_icon":0},{"id":"2518731582","title":"BioCryst制药盘中异动 早盘快速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518731582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518731582?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:25","pubTimestamp":1741616747,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时25分，BioCryst制药股票出现波动，股价急速下跌5.01%。截至发稿，该股报7.31美元/股，成交量35.2675万股，换手率0.17%，振幅4.16%。BioCryst制药股票所在的制药行业中，整体跌幅为2.11%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503102225479640433b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503102225479640433b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2516677559","title":"BioCryst制药盘中异动 早盘快速跳水7.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677559?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098751,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，BioCryst制药股票出现异动，股价快速下跌7.85%。截至发稿，该股报7.87美元/股，成交量23.2054万股，换手率0.11%，振幅4.36%。BioCryst制药股票所在的制药行业中，整体跌幅为0.02%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223231a25f04c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223231a25f04c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0},{"id":"2516379074","title":"BioCryst制药2024财年实现净利润-88.88百万美元，同比增加60.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516379074?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:00","pubTimestamp":1740758437,"startTime":"0","endTime":"0","summary":"3月1日，BioCryst制药公布财报，公告显示公司2024财年净利润为-88.88百万美元，同比增加60.85%；其中营业收入为4.51亿美元，同比增加36.25%，每股基本收益为-0.43美元。从资产负债表来看，BioCryst制药总负债9.66亿美元，其中短期债务35.45百万美元，资产负债比为0.51，流动比率为2.64。机构评级：截至2025年3月1日，当前有11家机构对BioCryst制药目标价做出预测，其中目标均价为15.91美元，其中最低目标价为8.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000046a25817fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000046a25817fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX"],"gpt_icon":0},{"id":"2514056016","title":"Citizens Capital Markets：重申BioCryst Pharma(BCRX.US)评级，由优于大市调整至优于大市评级, 目标价由18.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514056016","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514056016?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:51","pubTimestamp":1740498699,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申BioCryst Pharma(BCRX.US)评级，由优于大市调整至优于大市评级, 目标价由18.00美元调整至18.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25235148385221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BCRX"],"gpt_icon":0},{"id":"1173855464","title":"异动解读 | BCRX第四季度业绩疲软引发7.17%盘中大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1173855464","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173855464?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:33","pubTimestamp":1740407637,"startTime":"0","endTime":"0","summary":"BCRX(BioCryst制药)公司周一盘中大跌7.17%,引起市场广泛关注。这一波动与公司近期披露的2024年第四季度财报数据存在一定关联。\n\n数据显示,BCRX在该季度实现营收1.315亿美元,同比增长40.83%,超出市场预期。不过,公司每股收益为-0.13美元,低于分析师预期的-0.06美元,同比亦无改善。\n\n尽管营收增速喜人,但由于净利润持续亏损,加之EPS表现不佳,市场对BCRX未来增长前景的预期可能受到一定打击,进而引发投资者资金流出,促使股价承压下跌。值得关注的是,该公司日后的研发投入及新药上市进程也可能是股价波动的主要驱动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCRX"],"gpt_icon":0},{"id":"2513727313","title":"BioCryst制药盘中异动 股价大跌7.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513727313?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:30","pubTimestamp":1740407451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时30分，BioCryst制药股票出现异动，股价快速下跌7.06%。截至发稿，该股报8.56美元/股，成交量14.0755万股，换手率0.07%，振幅1.50%。BioCryst制药股票所在的生物技术行业中，整体涨幅为0.00%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223052962e982f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223052962e982f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX","BK4547","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":-0.036},{"period":"1month","weight":-0.1336},{"period":"3month","weight":-0.0868},{"period":"6month","weight":-0.2265},{"period":"1year","weight":-0.2064},{"period":"ytd","weight":-0.1769}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioCryst Pharmaceuticals, Inc.是一家特拉华州公司，最初成立于1986年。该公司是一家全球性生物技术公司，致力于改善遗传性血管性水肿和罕见病患者的生活。该公司利用结构引导药物设计方面的专业知识，目标是开发一流或一流的口服小分子和注射蛋白疗法，以针对难以治疗的罕见疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.02531},{"month":2,"riseRate":0.5,"avgChangeRate":-0.011235},{"month":3,"riseRate":0.354839,"avgChangeRate":0.014971},{"month":4,"riseRate":0.5625,"avgChangeRate":0.048894},{"month":5,"riseRate":0.5625,"avgChangeRate":0.062945},{"month":6,"riseRate":0.59375,"avgChangeRate":0.027194},{"month":7,"riseRate":0.5625,"avgChangeRate":0.113207},{"month":8,"riseRate":0.59375,"avgChangeRate":0.099672},{"month":9,"riseRate":0.34375,"avgChangeRate":-0.049493},{"month":10,"riseRate":0.5,"avgChangeRate":-0.046955},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.004698}],"exchange":"NASDAQ","name":"BioCryst制药","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioCryst制药(BCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioCryst制药,BCRX,BioCryst制药股票,BioCryst制药股票老虎,BioCryst制药股票老虎国际,BioCryst制药行情,BioCryst制药股票行情,BioCryst制药股价,BioCryst制药股市,BioCryst制药股票价格,BioCryst制药股票交易,BioCryst制药股票购买,BioCryst制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioCryst制药(BCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}